HK$5.34
0.74%
Hong Kong, Sep 18, 04:00 pm HKT. Closed.
ISIN
KYG2588M1006
Symbol
2616

Cstone Pharmaceuticals Target price 2026 - Analyst rating & recommendation

Cstone Pharmaceuticals Classifications & Recommendation

Buy
89%
Hold
11%

Cstone Pharmaceuticals Price Target

Target Price HK$17.24
Price HK$5.34
Potential
Number of Estimates 5
5 Analysts have issued a price target Cstone Pharmaceuticals 2027 . The average Cstone Pharmaceuticals target price is HK$17.24. This is higher than the current stock price. The highest price target is
HK$21.00 293.63%
register free of charge
, the lowest is .
A rating was issued by 9 analysts: 8 Analysts recommend Cstone Pharmaceuticals to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Cstone Pharmaceuticals stock has an average upside potential 2027 of . Most analysts recommend the Cstone Pharmaceuticals stock at Purchase.

Sales and Margin forecast 2026, 2027 & 2028

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Revenue Million HK$ 315.68 578.81
33.80% 83.55%
EBITDA Margin -132.31% -83.53%
1,577.88% 36.87%
Net Margin -162.10% 9.13%
623.75% 105.63%

5 Analysts have issued a sales forecast Cstone Pharmaceuticals 2026 . The average Cstone Pharmaceuticals sales estimate is

HK$579m
unlock
. This is
83.55% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
HK$748m 136.95%
unlock
, the lowest is
HK$460m 45.64%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 HK$316m 33.80%
2026
HK$579m 83.55%
unlock
2027
HK$2.4b 312.09%
unlock
2028
HK$1.1b 52.16%
unlock

6 Cstone Pharmaceuticals Analysts have issued a net profit forecast 2026. The average Cstone Pharmaceuticals net profit estimate is

HK$52.8m
unlock
. This is
110.33% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
HK$671m 231.08%
unlock
, the lowest is
HK$-525m 2.50%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 HK$-512m 379.15%
2026
HK$52.8m 110.33%
unlock
2027
HK$1.2b 2,077.91%
unlock
2028
HK$164m 85.72%
unlock

Net Margin

2025 -162.10% 623.75%
2026
9.13% 105.63%
unlock
2027
48.24% 428.37%
unlock
2028
14.41% 70.13%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share HK$ -0.37 0.04
362.50% 110.81%
P/E 150.30
EV/Sales 12.97

6 Analysts have issued a Cstone Pharmaceuticals forecast for earnings per share. The average Cstone Pharmaceuticals EPS is

HK$0.04
unlock
. This is
111.76% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
HK$0.45 232.35%
unlock
, the lowest is
HK$-0.36 5.88%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 HK$-0.37 362.50%
2026
HK$0.04 110.81%
unlock
2027
HK$0.78 1,850.00%
unlock
2028
HK$0.11 85.90%
unlock

P/E ratio

Current -15.82 47.78%
2026
150.30 1,049.85%
unlock
2027
6.90 95.41%
unlock
2028
48.31 600.14%
unlock

Based on analysts' sales estimates for 2026, the Cstone Pharmaceuticals stock is valued at an EV/Sales of

12.97
unlock
and an P/S ratio of
14.12
unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 23.81
2026
12.97 45.52%
unlock
2027
3.15 75.73%
unlock
2028
6.58 109.05%
unlock

P/S ratio

Current
2026
14.12 45.52%
unlock
2027
3.43 75.73%
unlock
2028
7.17 109.05%
unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today